Bicycle Therapeutics plc Interest Expense Nonoperating
Bicycle Therapeutics plc (BCYC) reported Interest Expense Nonoperating of $44.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- Bicycle Therapeutics plc interest expense nonoperating for the quarter ending 2026-06-30 was $44.00K, a 18.52% decline year-over-year.
- Bicycle Therapeutics plc interest expense nonoperating for the quarter ending 2026-03-31 was $48.00K, a 5.88% decline year-over-year.
- Bicycle Therapeutics plc interest expense nonoperating for the quarter ending 2025-12-31 was $57.00K, a 9.62% increase year-over-year.
- Bicycle Therapeutics plc interest expense nonoperating for the quarter ending 2025-09-30 was $44.00K, a 33.33% increase year-over-year.
- Bicycle Therapeutics plc interest expense nonoperating for fiscal 2025 was $206.00K, a 88.09% decline from fiscal 2024.
- Bicycle Therapeutics plc interest expense nonoperating for fiscal 2024 was $1.73M, a 46.98% decline from fiscal 2023.
- Bicycle Therapeutics plc interest expense nonoperating for fiscal 2023 was $3.26M, a 2.42% decline from fiscal 2022.
- Bicycle Therapeutics plc interest expense nonoperating for fiscal 2022 was $3.34M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.00K 10-Q · filed 2026-07-30 | $92.00K 10-Q · filed 2026-07-30 | $149.00K derived: sum of 3 quarters · filed 2026-07-30 | $193.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $48.00K 10-Q · filed 2026-04-30 | $105.00K derived: sum of 2 quarters · filed 2026-04-30 | $149.00K derived: sum of 3 quarters · filed 2026-04-30 | $203.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $101.00K derived: sum of 2 quarters · filed 2026-03-17 | $155.00K derived: sum of 3 quarters · filed 2026-07-30 | $206.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | $44.00K 10-Q · filed 2025-10-30 | $98.00K derived: sum of 2 quarters · filed 2026-07-30 | $149.00K 10-Q · filed 2025-10-30 | $201.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $54.00K 10-Q · filed 2026-07-30 | $105.00K 10-Q · filed 2026-07-30 | $157.00K derived: sum of 3 quarters · filed 2026-07-30 | $190.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $51.00K 10-Q · filed 2026-04-30 | $103.00K derived: sum of 2 quarters · filed 2026-04-30 | $136.00K derived: sum of 3 quarters · filed 2026-04-30 | $960.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $85.00K derived: sum of 2 quarters · filed 2026-03-17 | $909.00K derived: sum of 3 quarters · filed 2026-03-17 | $1.73M 10-K · filed 2026-03-17 |
| 2024-09-30 | $33.00K 10-Q · filed 2025-10-30 | $857.00K derived: sum of 2 quarters · filed 2025-10-30 | $1.68M 10-Q · filed 2025-10-30 | $2.50M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $824.00K 10-Q · filed 2025-08-08 | $1.65M 10-Q · filed 2025-08-08 | $2.46M derived: sum of 3 quarters · filed 2026-03-17 | $3.28M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $821.00K 10-Q · filed 2025-05-01 | $1.64M derived: sum of 2 quarters · filed 2026-03-17 | $2.46M derived: sum of 3 quarters · filed 2026-03-17 | $3.28M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.63M derived: sum of 2 quarters · filed 2026-03-17 | $2.46M derived: sum of 3 quarters · filed 2026-03-17 | $3.26M 10-K · filed 2026-03-17 |
| 2023-09-30 | $814.00K 10-Q · filed 2024-10-31 | $1.64M derived: sum of 2 quarters · filed 2024-10-31 | $2.44M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $821.00K 10-Q · filed 2024-08-06 | $1.63M 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $3.34M 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |